Cerevance's solengepras cuts OFF time in phase 3 Parkinson's trial

Cerevance reported that its oral non‑dopaminergic therapy, solengepras, produced meaningful improvements in both motor and non‑motor symptoms in a phase 3 Parkinson's disease study, rescuing the candidate after a prior phase 2 setback.

The trial enrolled 341 patients who received either 150 mg, 75 mg of solengepras or placebo once daily for 12 weeks alongside levodopa. The 150 mg dose cut average daily OFF time by 0.61 hours versus placebo and added 0.60 hours of ON time, with benefits evident as early as week 2.

Beyond motor gains, patients on the higher dose showed a 1.91‑point rise on a Parkinson’s rating scale and a 0.98‑point improvement in daytime sleepiness, indicating better daily functioning. Cerevance said it will pursue FDA approval based on these results.